Month: March 2017

Ageing Conference 2017

We are now living in a time where the first generation of people with haemophilia will have to confront the challenges of ageing. Many people with haemophilia can expect to live beyond their 70th or even 80th year. This is very reassuring and a testament to the improvement in comprehensive care and the availability of …

Ageing Conference 2017 Read More »

Information Meetings – New Haemophilia B Treatment

  Following a recent tender/procurement process undertaken by the Haemophilia Product Selection Board (which includes both haemophilia doctors and the Society), the recombinant factor IX coagulation factor concentrate used for the treatment of factor IX deficiency will be changed from Benefix to an Extended Half-Life factor IX concentrate called Alprolix for all people with factor …

Information Meetings – New Haemophilia B Treatment Read More »

Hepatitis C Open Conference

  Date: Saturday 13th May 2017 Venue: Castleknock Hotel, Castleknock, Dublin 15 This one‐day conference, (organised by the Irish Haemophilia Society) will be an opportunity for people with Hepatitis C, to receive updates on treatment, how to access treatment and what happens after treatment. THERE IS NO CHARGE TO ATTEND THIS CONFERENCE BUT REGISTRATION IS …

Hepatitis C Open Conference Read More »

Clinical Trials

Gene Therapy The National Coagulation Centre (NCC) will be holding special clinics this month to offer blood tests to people with severe factor IX deficiency to assess their suitability for possible inclusion in a Gene Therapy clinical trial. Special clinics will be held on the mornings of Tuesday 21st March and Friday 24th March. Any …

Clinical Trials Read More »

Long-term Safety and Efficacy Extension Study Data of ALPROLIX, Extended Half-life Treatment for Haemophilia B Patients

  Alprolix is the new extended half life treatment that will be available to haemophilia B patients in Ireland from April 2017. Alprolix will allow patients to infuse less frequently (typically once a week instead of twice a week.) Alprolix will also allow patients to maintain a higher trough level, meaning their factors levels won\’t …

Long-term Safety and Efficacy Extension Study Data of ALPROLIX, Extended Half-life Treatment for Haemophilia B Patients Read More »